The invention relates to methods of treating metabolic syndrome, or the specific disorders associated with metabolic syndrome, comprising the administration of norfluoxetine enriched for the (R) or (S) enantiomer conjointly with a statin, a calcium channel blocker, halofenate, captopril, or an imidazoline receptor agonist (e.g., an I.sub.1, I.sub.2, or I.sub.3 receptor agonist).